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Abstract
Objective To assess whether quantitative assessment of symptom reduction is a better outcome parameter than cyst volume
reduction for treatment success in patients treated by aspiration sclerotherapy.
Methods We included patients with symptomatic, large (> 5 cm), hepatic cysts from a randomized controlled trial
(NCT02048319). At baseline and 6 months after treatment, symptoms were assessed with the polycystic liver disease question-
naire (PLD-Q) and we measured cyst volume using ultrasonography. Patient-reported change in health was assessed on a 5-point
Likert scale (much worse to much better) after 6 months. We tested whether PLD-Q scores and cyst volumes changed after
aspiration sclerotherapy (responsiveness). Changes in PLD-Q scores and cyst volume were compared with change in health as a
measure of treatment success (discriminative ability). As secondary analysis, we compared baseline characteristics between
responders (improved) and non-responders (not improved).
Results We included 32 patients. Six months after treatment, 23 patients (72%) improved. Both PLD-Q score and cyst volume
significantly decreased (median 38 to 18 points, p < 0.001, and 479 to 68 mL, p < 0.001). Larger improvement in PLD-Q score
was associated with a positive change in health (p = 0.001), while larger proportional reduction in cyst volume was not signif-
icantly associated with health improvement after treatment (p = 0.136). Responders had larger baseline cyst volumes compared to
non-responders (median 624 mL [IQR 343–1023] vs. 322 mL [IQR 157–423] p = 0.008).
Conclusion Cyst diameter reduction does not reflect treatment success in aspiration sclerotherapy from patients’ perspective,
while symptoms measured with the PLD-Q can be used as a reliable outcome measure.
Key Points
• Cyst diameter reduction poorly reflects treatment success in aspiration sclerotherapy.
• Symptoms measured by the polycystic liver disease questionnaire (PLD-Q) is a better outcome measure than cyst volume
reduction for treatment success after aspiration sclerotherapy.
• Particularly patients with larger cysts (≥ 529 mL) benefit from aspiration sclerotherapy.
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Abbreviations
PLD Polycystic liver disease
PLD-Q Polycystic liver disease questionnaire
ROC Receiver operating characteristic
Introduction
Hepatic cysts are fluid-filled cavities varying in volume from a
fewmilliliters to liters [1].Most are found incidentally as isolated
cysts but some patients present with inherited polycystic liver
disease (PLD) [2]. Large space-occupying cysts may cause
symptoms such as abdominal pain or discomfort [3]. Aminimal-
ly invasive treatment option for symptomatic large cysts is
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aspiration sclerotherapy, which involves complete drainage of
cyst fluid followed by injection of a sclerosing agent that will
eliminate the fluid-producing cyst epithelium [4].
Most studies use cyst volume reduction as a rather technical
endpoint to define the efficacy of aspiration sclerotherapy [5–8].
Only a limited number of studies investigated patient-reported
outcomemeasures such as symptomatic relief, and none of these
studies used this as primary endpoint [9]. Yet, from a patient-
centered view, clinical response after the procedure is the most
relevant outcome as it is the patient’s independent perception of
symptoms, functioning, and well-being that counts most.
Capturing the clinical response can be assessed using gener-
ic patient-related outcome measures that encompass a wide
range of domains, including physical, mental, and social do-
mains. These generic instruments such as the SF-36 lack the
granularity and specificity that is needed to capture domains
that are most disturbed by symptomatic hepatic cysts [10].
Recently, a validated polycystic liver disease questionnaire
(PLD-Q) was developed. This disease-specific tool assesses
frequency and discomfort of 13 disease-specific symptoms in
PLD [11]. Symptoms arising from the presence of large sim-
ple cysts match with those in PLD [12], although it is unclear
whether PLD-Q is a valuable instrument to evaluate clinical
response in patients with large hepatic cysts treated with aspi-
ration sclerotherapy.
The primary aim of this study was to assess the best outcome
measure for patient-reported treatment success in aspiration
sclerotherapy. Treatment success was measured by a patient-
completed Likert scale for change in health as reference and
compared to the PLD-Q and cyst volume reduction. As a sec-
ondary objective, we identified baseline characteristics associ-
ated with treatment success at 6 months after therapy.
Methods
Study population and design
We performed a post hoc analysis including patients from a
previously conducted randomized, double-blind, placebo-
controlled clinical trial that assessed the additional effect of the
somatostatin analogue pasireotide on aspiration sclerotherapy
(NCT 02048319) [8]. This study was conducted at Radboud
University Medical Center, Nijmegen, the Netherlands, from
April 2014 to April 2016 and approved by the Institutional
Ethical Review Board. Informed consent was obtained from
all patients. All patients received aspiration sclerotherapy for
symptomatic, large (> 5 cm), non-neoplastic, non-hydatid he-
patic cysts. Only solitary and dominant cysts (largest cyst in
PLD) that were a reasonable explanation for the symptomswere
included. An ultrasound-guided cyst puncture was performed
for cyst fluid drainage. Subsequently, ethanol was injected and
re-aspirated after 10 min of sclerotherapy. Patients were
randomized (1:1) to two additional injections of pasireotide
(twoweeks prior and twoweeks following aspiration sclerother-
apy) or placebo. Endpoints included proportional change (%) in
cyst volume and change in symptoms after 6-month follow-up.
At 6 months, this study showed a strong reduction of the cyst
volume without added beneficial effect of pasireotide (83.1% in
pasireotide-arm versus 86.9% in placebo group, p = 0.90).
Treatment success: change in health
In the era of patient-centered care, patients’ judgment is often
used as outcome measure for treatment success [13]. Patients
were asked to rate their change in health on a five-point Likert
scale (much worse to much better) 6 months after treatment.
We defined patients that improved (somewhat or much better)
as responders, while patients that did not improve (about the
same, worse, and much worse) were classified as non-
responders to aspiration sclerotherapy. The use of this out-
come measure for treatment success in our population was
validated with two other frequently used patient-reported out-
comes (see Supplementary File) [14, 15].
Clinical outcome
To quantify changes in symptoms, patients completed the
PLD-Q (version 1) on paper in person at baseline and at a
follow-up visit 6 months after treatment [11]. The question-
naire included 13 symptoms that can be summed into a total
PLD-Q score, ranging from 0 (asymptomatic) to 100 (severely
symptomatic). Scoring and missing values were handled fol-
lowing the user manual [11]. For each patient, clinical re-
sponse was defined as the median change in PLD-Q total
score 6 months after treatment.
Morphological outcome
Three-foldedmeasurements of cyst volumeswere performed by
two blinded investigators in each patient with ultrasonography
using a 3.5-MHz convex transducer (Acuson X150™, Siemens
Healthineers) at baseline and 6 months after treatment. Cyst
volume was calculated by multiplying the mean orthogonal
diameters using the ellipsoid formula (D1 * D2 * D3 * 0.523)
[16]. For each patient, morphological response was defined as
the median proportional change (%) in cyst volume of the treat-
ed cyst 6 months after aspiration sclerotherapy. Figure 1 shows
an example of the cyst measurements.
Responsiveness and discriminative ability
To assess whether change in PLD-Q score is a more appropriate
tool than cyst volume reduction to determine treatment success
in patients with solitary cysts or PLD, we measured responsive-
ness and discriminative ability of these two outcome measures.
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Responsiveness is defined as the ability of an outcome measure
to detect change over time, while discriminative ability is the
degree to which a test can distinguish between groups of pa-
tients [17].
Statistics
Wepooled intervention and placebo arms for all analyzes as there
was no beneficial effect of pasireotide on cyst volume reduction.
Baseline characteristics were presented as absolute numbers and
percentage or median and interquartile range. To assess whether
we could combine patients with solitary cysts and PLD patients,
we compared patient characteristics and baseline scores with
Mann-Whitney U test or chi-square when appropriate.
We tested responsiveness of the PLD-Q and cyst volume
by comparing pre- and 6 months post-treatment values with
Wilcoxon signed-rank test. To assess discriminative ability,
we tested whether median changes in PLD-Q scores and me-
dian proportional cyst volume reduction at 6 months were
significantly different across patient-reported change in health
(much worse to much better) ratings using Kruskal Wallis test.
The categories Bsomewhat worse^ and Bmuch worse^ were
combined for analyses as the number of patients in these cat-
egories were very low. Thereafter, differences in change after
treatment between responders and non-responders were also
analyzed with Wilcoxon signed-rank test.
We compared baseline characteristics (gender, age, cyst
volume, hemorrhagic cyst fluid, solitary or PLD, baseline
PLD-Q score) between responders and non-responders
with Mann-Whitney U test or chi-square when appropriate.
Significant continuous factors were further explored with
receiver operating characteristic (ROC) analysis to assess
which cutoff point differentiated best between responders
and non-responders. This cutoff point was determined by
maximizing the Youden index of a ROC curve [18].
P values of < 0.05 were considered as statistical significant
in the primary analysis. To select characteristics of response,
we corrected for multiple testing using a Bonferroni correction
and selected only characteristics with p values of < 0.0083.
Analyses were performed with IBM SPSS Statistics version
22 (SPSS Inc.).
Results
From the 34 patients included in the original trial, two
patients were excluded because of failed aspiration sclero-
therapy (n = 1) or missing baseline PLD-Q (n = 1).
Baseline characteristics are depicted in Table 1. There were
no significant baseline differences between patients with
solitary cysts and PLD, enabling us to pool them.
Fig. 1 Example of ultrasound measurement of cyst volume at baseline
(A, 220 mL) and after 6 months (B, 20 mL). Cyst volume was calculated
bymultiplying the mean orthogonal diameters using the ellipsoid formula
(D1 * D2 * D3 * 0.523). In D1, we measured the cysts medio-lateral
direction, D2 dorso-ventral direction, and D3 in cranio-caudal direction








Age, years 54 (48 to 61) 52 (49 to 61) 55 (47 to 61) 0.667
Female sex, n (%) 30 (94) 11 (100) 19 (90) 0.290
PLD-Q total score 39 (26 to 52) 44 (28 to 64) 37 (25 to 51) 0.531
Cyst volume, mL 479 (260–847) 378 (211–1253) 491 (298–728) 0.938
Hemorrhagic cyst fluid, n (%) 14 (44) 5 (45) 9 (43) 0.710
Variables are shown as median (IQR) unless noted otherwise. Differences between patients with solitary cysts and
PLD are analyzed by Mann-Whitney U test or chi-square when appropriate
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Responsiveness
Six months after aspiration sclerotherapy, there was a signifi-
cant decrease in total PLD-Q score (median 38 points [26–52]
to 18 points [11–33], p < 0.001) and cyst volume (median
479 mL [260–847] to 68 mL [11–156], p < 0.001). Most
symptoms of the PLD-Q decreased after treatment (p < 0.05)
(Fig. 2), except there was no significant change in nausea (p =
0.278) and fear or anxiety for the future (p = 0.831).
Discriminative ability
As defined by patient-reported treatment success, most pa-
tients rated their change in health as improved after therapy
(Bsomewhat better^ n = 10, Bmuch better^ n = 13), six patients
remained the same and health of three patients deteriorated
(Bsomewhat worse^ n = 1, Bmuch worse^ n = 2). In total, 23
patients (72%) could be defined as responder.
Table 2 shows an orderly improvement inmedian changes in
PLD-Q total score classified by change in health (p = 0.001).
Patient that rated themselves as Bmuch better^ decreased a me-
dian 28 points (-37 to -23), while patients that rated themselves
as Bworse^ increased by a median 1 point (-14 to 3).
Median proportional reduction in cyst volumewas not signif-
icantly different across the health status groups (p = 0.136). Cyst
volume reduction of patients that scored themselves as Bbetter^
was similar to patients that got Bworse^ (median 72% [52 to 89]
vs. 87% [66 to 97]).
Differences between changes in symptom scores of the
PLD-Q after therapy between responders and non-
responders are shown in Table 3. Responders had signif-
icant decreases in the symptoms lack of appetite, early
satiety, pain in side, abdominal pain, shortness of breath,
limited mobility, tiredness, dissatisfaction abdomen size,
and problems with intercourse, while non-responders did
not. The symptoms fullness and pain/pressure in ribcage
decreased significantly in both groups.
Baseline characteristics of response
Responders had significantly larger baseline cyst volumes
compared to non-responders (median 624 mL [343–1023]
vs. 322 mL [157–423] p = 0.008). ROC-curve analysis
revealed that a baseline cyst volume larger than 529 mL
was the best cutoff point to identify responders (AUC
0.802 (95% CI 0.651–0.953, p = 0.009; sensitivity 61%;
specificity 100% (Fig. 3). Age (p = 0.213), gender (p =
0.361), solitary or PLD (p = 0.365), hemorrhagic cyst flu-
id (p = 0.959), and baseline PLD-Q score (p = 0.621) were
not significantly different across responders and non-
responders.
Fig. 2 Symptoms prior to aspiration sclerotherapy (AS) compared with 6 months after therapy. *p < 0.05, **p < 0.001
Table 2 Change in health
compared with change in PLD-Q
score and cyst volume reduction
6 months after sclerotherapy
Self-reported rating of change Change in PLD-Q score Cyst volume reduction (%)
Much better, n = 13 -28 (-37 to -23) 72 (52 to 89)
Somewhat better, n = 10 -12 (-17 to -5) 90 (91 to 99)
About the same, n = 6 -9 (-20 to 2) 79 (60 to 97)
Worse, n = 3 1 (-14 to 3)a 87 (66 to 97)a
Data presented as median [IQR]
aWorse is a combination of the self-reported categories somewhat worse (n = 1) and much worse (n = 2)
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Discussion
Our study showed that in a population of patients with large
hepatic cysts, the PLD-Q and cyst volume were both highly
responsive to change after aspiration sclerotherapy. We found
that PLD-Q discriminated between patients who clinically
benefited from this therapy or not, while cyst volume changes
did not. We demonstrate that patients with larger cysts
(≥ 529 mL) benefit more from aspiration sclerotherapy after
6 months than patients with smaller cysts at baseline.
The results of our study emphasize the dissociation between
morphological response (cyst volume) and patient-reported out-
come measures (PLD-Q) after aspiration sclerotherapy.
Although larger baseline cyst volume was associated with a
better outcome, dynamic changes in volume did not correlate
with patient-reported treatment success. In our study, a propor-
tion of patients reported treatment success after only a small
reduction in cyst volume. This accords with previous literature
indicating that one third of patients with suboptimal morpho-
logical response achieved complete clinical response [19].
A disease-specific symptom questionnaire is able to evalu-
ate, monitor, and examine the impact of care. In addition, it
can discriminate which symptoms will respond to therapy. We
found that nausea did not improve after aspiration sclerother-
apy. Therefore, this procedure should not be performed in case
nausea is the only presenting symptom. Fullness and pain/
pressure in ribcage decreased significantly in the non-
responder group, but did not lead to treatment success as
judged by these patients. This might suggest that these symp-
toms are of minor relevance to this specific patient population.
Although baseline PLD-Q scores could not predict responders
to treatment in our study, the PLD-Q provides quantitative
response data of symptom relief and maps whether new symp-
toms arise (related or not to cyst of interest).
Currently, there is a large paradigm shift in medicine from
morphological outcomes to patient-reported outcomes [20].
Table 3 Differences in symptom
scores of the PLD-Q 6 months






Change in score p value* Change in score p value
Fullness -2 (-5 to 0) 0.002 -1 (-3 to -1) 0.040
Lack of appetite -4 (-6 to -2) 0.042 -3 (-4 to 1) 0.330
Early satiety -1 (-4 to 0) 0.004 -2 (-3 to 0) 0.071
Nausea 2 (2 to 4) < 0.001 4 (2 to 4) 0.007
Pain/pressure rib cage -4 (-5 to -2) < 0.001 -3 (-4 to -1) 0.016
Pain in side -3 (-6 to -2) < 0.001 0 (-3 to 1) 0.167
Abdominal pain -2 (-3 to -1) < 0.001 0 (-2 to 1) 0.786
Shortness of breath -2 (-4 to -1) < 0.001 0 (-4 to 2) 0.497
Limited mobility -3 (-4 to -1) < 0.001 0 (-3 to 1) 0.750
Tiredness -2 (-2 to 0) 0.002 0 (-2 to 1) 0.586
Fear/anxiety future 0 (-2 to 0) 0.217 1 (0 to 3) 0.102
Dissatisfaction abdomen size -1 (-3 to 0) 0.027 -1 (-2 to 0) 0.149
Problems with intercourse -1 (-4 to 0) 0.018 0 (-1 to 0) 0.180
Changes in PLD-Q symptoms presented as median (IQR). *p value of pre- and post-treatment scores using
Wilcoxon signed-rank test
Fig. 3 ROC analysis of baseline cyst volume and change in health.
Patients were divided into two groups according to their change in
health: improved (better and much better) and not improved (about the
same, worse or much worse). A baseline cyst volume of ≥ 529 mL had a
sensitivity and specificity of respectively 61% and 100% for
improvement (AUC 0.802, p = 0.009)
3066 Eur Radiol (2019) 29:3062–3068
Patient-reported outcomes have gained acceptance as valid
primary endpoint in studies of patients with symptomatic con-
ditions [21]. Despite increased popularity and use of patient-
reported outcome measures in radiological literature, these
outcomes are still underused. Patient-reported outcomes as-
sess the effect of trial interventions from patients’ perspectives
and are particularly useful when interventions aim to improve
symptoms or functional status. Our data highlight that patient-
focused outcomes may be a valuable complement to the tra-
ditional clinical outcomes.
Although aspiration sclerotherapy is a highly effective pro-
cedure in terms of cyst volume reduction, 28% of patients
failed to have symptomatic improvement. This highlights that
a better patient selection is needed to increase its yield. Results
of this study suggest that patients with a cutoff value
> 529 mL, corresponding with a diameter of approximately
10 cm (calculated with ellipsoid formula), will benefit from
therapy. The few available RCTs use no or a smaller cyst
diameter cutoff for inclusion [7, 8, 22]. The cutoff value found
in our study may be considered as evidence-based inclusion
criteria for clinical trials in this field, although replication of
our results is desired.
The strength of this study is that we used data of a random-
ized controlled trial with protocolized measurement points
and an extensively validated questionnaire for polycystic liver
disease. With this powerful methodology, we were able to
assess which outcome measure was most appropriate to eval-
uate treatment success in aspiration sclerotherapy.
Limitation of this study is the small sample size. However,
changes in cyst volume and symptoms were large and even
using a stricter p value for our secondary analysis, baseline cyst
volume remained a significant predictor for treatment success.
We used a questionnaire that was originally developed for
polycystic liver disease. In this study, 11 (34%) patients had a
solitary cyst. Based on chart review, all presenting symptoms
of patients with solitary cysts were included in the PLD-Q.
The PLD-Q correlated with patient-reported treatment suc-
cess, confirming criterion validity, and it was responsive to
therapy [17]. Although extensively assessed in cohorts of
polycystic liver disease patients, reproducibility of the PLD-
Q (the ability to produce the same answers in similar condi-
tions) was not assessed in this specific population.
Moreover, 6 months of follow-up time of this study was
relatively short. Possibly, patients with a clinical response and
a limited cyst volume reduction may have earlier recurrence of
symptoms than patients with a strong cyst volume reduction.
Hypothetically, these patients may become non-responder at
12 months which may align clinical and morphological re-
sponse. Longer follow-up is needed to further investigate this.
This study allows us to provide management advice on
follow-up after aspiration sclerotherapy. Some centers per-
form routine follow-up with ultrasonography of the treated
cyst after the procedure. The implication of our results is that
follow-up with regular measurement of cyst size does not
contribute to the magnitude of treatment success and may be
thus be abolished. In case symptoms recur, cyst measurement
in indicated.
In conclusion, cyst diameter reduction poorly reflects treat-
ment success of aspiration sclerotherapy from a patient per-
spective, while the PLD-Q can be used as a reliable outcome
measure. Our results suggest that patients with cysts > 500 mL
particularly benefit from treatment.
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